Table 1 Patients’ characteristics on admission stratified according to the baseline platelet count.

From: Thrombocytosis in COVID-19 patients without myeloproliferative neoplasms is associated with better prognosis but higher rate of venous thromboembolism

 

Plts < 150 × 109/L (1)

Plts 150–449 × 109/L (2)

Plts ≥ 450 × 109/L (3)

P value

Number of pts

1120 (19.1%)

4486 (76.3%)

270 (4.6%)

–

Age (years)

74 (64.5–82)

72 (62–81)

71 (61–80)

P < 0.001a (1 vs. 2; 2 vs. 3)a

Sex

Male

714 (63.7%)

2438 (54.3%)

147 (54.4%)

P < 0.001a (1 vs. 2; 1 vs. 3)a

Female

406 (36.2%)

2048 (45.7%)

123 (45.6%)

 

Time from symptoms onset (days)

4 (1–8)

6 (2–10)

7 (2–12)

P < 0.001a (1 vs. 2; 1 vs. 3; 2 vs. 3)a

Pneumonia

1018 (90.9%)

4044 (90.1%)

239 (88.5%)

P = 0.476

COVID-19 severity

Mild

93 (8.3%)

407 (9.1%)

28 (10.4%)

P = 0.219

Moderate

57 (5.1%)

204 (4.5%)

20 (7.4%)

 

Severe

803 (71.7%)

3190 (71.1%)

175 (64.8%)

 

Critical

167 (14.9%)

685 (15.3%)

47 (17.4%)

 

ECOG status on admission

3 (2–4)

2 (1–3)

2 (1–4)

P < 0.001a (1 vs. 2; 1 vs. 3)a

MEWS symptom severity

2 (1–4)

2 (1–4)

2 (1–4)

P = 0.598

Charlson comorbidity index

5 (3–7)

4 (2–6)

4 (2–6)

P < 0.001a (1 vs. 2; 1 vs. 3)a

Arterial hypertension

772 (68.9%)

3074 (76.5%)

171 (63.3%)

P = 0.185

Diabetes mellitus

346 (30.9%)

1319 (29.4%)

77 (28.5%)

P = 0.569

Hyperliproteinemia

237 (21.2%)

1037 (23.1%)

52 (19.3%)

P = 0.155

Obesity

280 (25%)

1383 (30.8%)

62 (23%)

P < 0.001a (1 vs. 2; 2 vs. 3)a

Active smoking

57 (5.1%)

255 (5.7%)

17 (6.3%)

P = 0.650

Active malignancy

156 (13.9%)

372 (8.3%)

32 (11.9%)

P < 0.001a (1 vs. 2; 2 vs. 3)a

Malignancy typeb

   

P < 0.001a

Lung cancer

8 (5.1%)

54 (14.5%)

5 (15.6%)

 

Breast cancer

6 (3.8%)

21 (5.6%)

1 (3.1%)

 

Colon cancer

10 (6.4%)

53 (14.2%)

5 (15.6%)

 

Stomach cancer

4 (2.6%)

10 (2.7%)

2 (6.2%)

 

Hematologic malignancy

82 (52.6%)

75 (20.2%)

3 (9.4%)

 

Gynecologic malignancy

5 (3.2%)

16 (4.3%)

5 (15.6%)

 

Other

41 (26.3%)

143 (38.4%)

11 (34.4%)

 

Active anticancer therapy

62 (5.5%)

76 (1.7%)

7 (2.6%)

P < 0.001a (1 vs. 2; 1 vs. 3)a

Liver cirrhosis

40 (3.6%)

31 (0.7%)

1 (0.4%)

P < 0.001a (1 vs. 2; 1 vs. 3)a

Chronic kidney disease

191 (17.1%)

445 (9.9%)

24 (8.9%)

P < 0.001a (1 vs. 2; 1 vs. 3)a

Prior aspirin use

188 (16.8%)

819 (18.3%)

59 (21.9%)

P = 0.142

Prior anticoagulant therapy

287 (25.6%)

1023 (22.8%)

60 (22.2%)

P = 0.123

WBC

×109/L

5.8 (4.1–8.2)

8.3 (6.1–11.5)

11.2 (8.4–14.8)

P < 0.001a (1 vs. 2; 1 vs. 3; 2 vs. 3)a

Abs. neutrophils

×109/L

4.4 (2.9–6.6)

6.7 (4.6–9.7)

8.8 (6.3–12.6)

P < 0.001a (1 vs. 2; 1 vs. 3; 2 vs. 3)a

Abs. lymphocytes

×109/L

0.7 (0.5–1)

0.8 (0.6–1.2)

1 (0.7–1.6)

P < 0.001a (1 vs. 2; 1 vs. 3; 2 vs. 3)a

Abs. monocytes

×109/L

0.3 (0.2–0.5)

0.43 (0.3–0.6)

0.59 (0.4–0.8)

P < 0.001a (1 vs. 2; 1 vs. 3; 2 vs. 3)a

Abs. eosinophils

×109/L

0 (0–0.02)

0.01 (0–0.03)

0.02 (0–0.1)

P < 0.001a (1 vs. 2; 1 vs. 3; 2 vs. 3)a

Abs. basophils

x109/L

0.01 (0–0.03)

0.02 (0–0.05)

0.04 (0.02–0.08)

P < 0.001a (1 vs. 2; 1 vs. 3; 2 vs. 3)a

Hemoglobin

g/L

127 (110–141)

129 (116–142)

120 (105–132)

P < 0.001a (1 vs. 2; 1 vs. 3; 2 vs. 3) a

RDW

%

14.4 (13.5–15.7)

13.9 (13.3–14.9)

14.1 (13.4–15.3)

P < 0.001a (1 vs. 2; 1 vs. 3; 2 vs. 3)a

Platelets

×109/L

119 (96–136)

240 (195–302)

530 (481–596)

P < 0.001a (1 vs. 2; 1 vs. 3; 2 vs. 3)a

MPV

fL

9.5 (8.8–10.4)

8.9 (8.3–9.6)

8.5 (8.1–9)

P < 0.001a (1 vs. 2; 1 vs. 3; 2 vs. 3)a

Ferritin

µg/L

858 (416–1745)

756 (408–1375)

745 (387–1300)

P = 0.003a (1 vs. 2; 1 vs. 3)a

d-dimers

mg/L FEU

1.34 (0.7–3.4)

1.29 (0.69–3.2)

2 (1–4.2)

P < 0.001a (1 vs. 3; 2 vs. 3)a

LDH

U/L

346 (251–482)

364 (264–490)

343 (272–461)

P = 0.073

CRP

mg/L

80.7 (38.7–135.4)

89.3 (39.7–151.6)

91.4 (40.3–150.7)

P = 0.012a (1 vs. 2)a

IL-6

pg/mL

57.9 (27.9–120.2)

43.1 (14.4–97.8)

17.5 (5.6–128.3)

P < 0.001a (1 vs. 2; 1 vs. 3)a

  1. Results are presented as median and interquartile range for continuous variables which are compared between groups using the Kruskal–Wallis ANOVA and post-hoc test by Conover. Categorical variables are presented as frequencies and percentages and are compared between groups using the Χ2 test.
  2. Plts platelets, pts patients, ECOG Eastern Cooperative Oncology Group, MEWS Modified Early Warning Score, WBC white blood cells, Abs. absolute, RDW red blood cell distribution width, MPV mean platelet volume, LDH lactate dehydrogenase, CRP C-reactive protein, IL interleukin.
  3. aStatistically significant at level P < 0.05.
  4. bPercentage of patients with active malignancy is shown.
Back to article page